Targeting the mTOR pathway in ovarian cancer. How to follow-up advanced-stage serous borderline tumors of the ovary: Analysis of the mode of diagnosis of recurrence in patients with stage II-III ...
Thymidylate synthase (TS) gene copy number in NSCLC. Background: Immunomagnetic EpCAM-based methods are successfully used to enrich and enumerate circulating tumor cells (CTCs) in metastatic breast ...
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that the ...
Expert Rev Proteomics. 2013;10(6):579-589. Target protein Examples of cell/tissue types which express this protein Ref. EpCAM (also called HEA or BerEP4) Epithelial cells such as breast, lung and ...
- 28% confirmed response rate (5/18) per RECIST v1.1 in unselected patients across doses prioritized for expansion (7.2, 8.6 and 10 mg/kg Q3W)- "EpCAM is a high potential and broadly expressed cancer ...
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented ...
SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...
- 28% confirmed response rate (5/18) per RECIST v1.1 in unselected patients across doses prioritized for expansion (7.2, 8.6 and 10 mg/kg Q3W)- - 3 of 7 evaluable patients (43%) with confirmed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback